Key Takeaways Amarin reported Q4 adjusted EPS of 1 cent, beating estimates despite a 21% revenue decline.AMRN's Vascepa sales fell 23% year over year, hit by lower U.S. prices and Europe's Recordati shift.Amarin achieved positive Q4 cash flow and targets $70M in annual cost savings.Amarin Corporation (AMRN) reported adjusted earnings of 1 cent per share for the fourth quarter of 2025, beating the Zacks Consensus Estimate of a loss of $1.27. The company had reported an adjusted loss of 2 cents per share in t ...

Amarin logo 3 Biotech Stocks Gaining Momentum Amarin (NASDAQ:AMRN) executives told investors that 2025 marked a “substantial achievement” year as the company advanced a strategic pivot toward a more partnered international commercial model and executed a global restructuring aimed at lowering its operating expense base. On the company’s fourth-quarter and full-year 2025 earnings call, management highlighted a new long-term agreement with Recordati to commercialize VAZKEPA in Europe, ongoing efforts to ...

Amarin Corporation (NasdaqCM:AMRN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsAaron Berg - President and CEODevin Sullivan - VP of Investor RelationsPeter Fishman - CFOConference Call ParticipantsNone - AnalystNone - AnalystOperatorPlease note this conference is being recorded. I would now like to turn the conference call over to Devin Sullivan, Investor Relations for Amarin.Devin SullivanThank you for your time and attention this morning as we discuss Amarin's 2025 fourth quart ...

Amarin Corporation (NasdaqCM:AMRN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker2Please note this conference is being recorded. I would now like to turn the conference call over to Devin Sullivan, Investor Relations for Amarin.Speaker1Thank you for your time and attention this morning as we discuss Amarin's 2025 fourth quarter and full year financial results. On the call today are Aaron Berg, President and Chief Executive Officer, and Peter Fishman, Chief Financial Officer. Other members of th ...

EVIDENCE-BASED THERAPY TO REDUCE LIFE-THREATENING CARDIOVASCULAR EVENTS Company Overview NASDAQ: AMRN FEBRUARY 2026 Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (icosapent ethyl) (VAZKEPA® in Europe and in other territories), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and liti ...

Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDA ...

DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month emphasizing a message that cannot wait: the United States has an opportunity to significantly reduce heart attacks, strokes, and cardiovascular deaths by prioritizing the use of proven, existing therapies that are widely available, yet significantly underutilized. D ...

DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:0 ...

Core Viewpoint - The U.S. Supreme Court's decision to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa may significantly impact generic drug manufacturers and the "skinny label" strategy [1] Group 1: Patent Dispute - The case centers around Amarin Pharma's Vascepa, which is a cardiovascular drug [1] - The outcome of this dispute could set a precedent affecting the generic drug market [1] Group 2: Implications for Generic Drug Makers - The ruling may influence how generic drug makers approach the development and marketing of their products [1] - The "skinny label" strategy, which allows generics to avoid patent infringement by omitting certain indications, could be affected by the court's decision [1]

Financial Performance - Amarin Corporation plc reported a year-end 2025 cash balance of $303 million, reflecting a growth of $16 million compared to $287 million in Q3 2025 [3] - The company expects its fiscal Q4 2025 net revenue to be in the range of $48 to $53 million, with fiscal year 2025 net revenue projected to be between $212 to $217 million [3] Operational Highlights - The company achieved positive cash flow in fiscal Q4 2025 earlier than previously forecasted, driven by a significant reduction in operating expenses and a long-term partnership with Recordati S.p.A. to commercialize VAZKEPA® across 59 countries, focusing on Europe [1] - Amarin believes it is on track for sustainable positive annual cash flow in 2026, supported by a full year of cost savings from its restructuring plan, with most expenses related to the plan already incurred in 2025 [2] Company Overview - Amarin Corporation plc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting cardiovascular health, specifically developing and commercializing Vascepa capsules [4]